title: Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
abstract: The aim was to compare the two most commonly recommended chemotherapy regimens (platinum-based chemotherapy and platinum-taxane combination) with non-platinum-based chemotherapy and those with no chemotherapy in a large nationwide and population-based cohort of patients with ovarian cancer with up to 17 years of follow-up. We studied 12,181 patients diagnosed with stages I-IV ovarian cancer at age ≥ 65 in 1991-2005 from the 16 areas of the United States. We also performed matched cohort analyses based on conditional probability of receiving platinum chemotherapy in 3,428 patients. In patients with early stage ovarian cancer, those who received platinum-taxane combination had the highest 5-year all-cause (62.5 %) and cancer-specific (65.1 %) survival rates, as compared to 51.5 and 63.7 % in those without chemotherapy. After adjusting for potential confounders, hazard ratios of all-cause mortality (0.66, 95 % CI 0.55-0.79) and cancer-specific mortality (0.74, 0.61-0.90) were significantly lower in patients receiving platinum-taxane combination as compared to those without chemotherapy. Among patients with late-stage ovarian cancer, risks of mortality were significantly reduced in patients who received both platinum and taxane (0.38, 0.36-0.41 for all-cause mortality; 0.40, 0.37-0.42 for cancer-specific mortality). Dose-response relationship appeared strong within each of the three chemotherapy regimens. These results and trends were almost identical in the matched cohort. Platinum-taxane combination chemotherapy and platinum-based chemotherapy without taxane were effective in prolonging survival with a significant dose-response relationship among patients with late-stage ovarian cancer. Among those with early stage tumors, platinum-taxane combination appeared more effective than other chemotherapy regimens.
authors.affiliation: Division of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, University of Texas Health Science Center at Houston, 1200 Herman Pressler Drive, Room RAS-E631, Houston, TX 77030, USA. xianglin.l.du@uth.tmc.edu
authors.forename: Xianglin L
authors.initials: XL
authors.lastname: Du
authors.forename: Rohan C
authors.initials: RC
authors.lastname: Parikh
authors.forename: David R
authors.initials: DR
authors.lastname: Lairson
authors.forename: Sharon H
authors.initials: SH
authors.lastname: Giordano
authors.forename: Putao
authors.initials: P
authors.lastname: Cen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D002945:Cisplatin; D015331:Cohort Studies; D057186:Comparative Effectiveness Research; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017239:Paclitaxel; D017671:Platinum Compounds / Q000627:therapeutic use*; D018426:SEER Program; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D001952:Bridged-Ring Compounds; D017671:Platinum Compounds; D043823:Taxoids; C080625:taxane; D017239:Paclitaxel; D002945:Cisplatin